VF in the News

FDA Approves Otezla®for the Treatment of Oral Ulcers in Behcet’s Disease

Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...

Read more

Penn’s Giant Cell Arteritis Fast-Track Program Provides Rapid Evaluation

The tricky part of giant cell arteritis (GCA) is the need for rapid evaluation, given the high risk of rapid vision loss and the importance of getting appropriate diagnostic tests, such as a temporal artery biopsy, soon after starting treatment. Unfortunately, there are not a lot of outpatient programs that…...

Read more

The OHSU Vasculitis Center: Specializing in Multidisciplinary Care

The most common form of vasculitis in adults over the age of 50 is giant cell arteritis (GCA), an inflammation of the blood vessels that primarily affects the head—especially the temples and scalp—but also arteries in other parts of the body, including the aorta. Early diagnosis is critical in GCA…...

Read more

Dr. Stephanie Garner Named Recipient of 2020 VCRC-VF Fellowship Award

Stephanie Garner, MD, MSc, FRCPC, developed an interest in vasculitis as an internal medicine resident at the University of Calgary in Alberta, Canada, while admitting a patient to its nephrology service. The patient had pulmonary renal syndrome—respiratory failure that involves bleeding in the lungs and kidney failure—due to ANCA-associated vasculitis.…...

Read more

Open Study: Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Brief Summary:  March 20, 2020 Primary Objective: To evaluate the efficacy of KEVZARA (sarilumab) in patients with polymyalgia rheumatica (PMR) as assessed by the proportion of subjects with sustained remission for sarilumab with a shorter corticosteroid (CS) tapering regimen as compared to placebo with a longer CS tapering regimen. Secondary…...

Read more

Open Study: Evaluation of Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis

Brief Summary: Primary Objective: To evaluate the efficacy of sarilumab in patients with giant cell arteritis (GCA) as assessed by the proportion of patients with sustained remission for sarilumab compared to placebo, in combination with a corticosteroid (CS) tapering course. Secondary Objective: To demonstrate the efficacy of sarilumab in patients…...

Read more